Phase 2/3 clinical study of HP-3150 in patients with cancer pain.
Phase of Trial: Phase II/III
Latest Information Update: 01 Dec 2016
At a glance
- Drugs HP 3150 (Primary)
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- Sponsors Hisamitsu Pharmaceutical
- 30 Nov 2016 Status changed from recruiting to completed.
- 29 Aug 2016 According to a Hisamitsu Pharmaceuticals media release, based on an investigation of the results of this trial company will decide whether to continue or stop the development.
- 01 Mar 2016 New trial record